Rationale for the Use of Insulin Sensitizers to Prevent Cardiovascular Events in Type 2 Diabetes Mellitus

American Journal of Medicine

Volumn 120, Issue 9 SUPPL. 2, 2007, Pages

  Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Hyperinsulinemia; Insulin; Insulin sensitizer; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C REACTIVE PROTEIN; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR 1; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY STENT; DISEASE ASSOCIATION; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERINSULINEMIA; HYPERPLASIA; IMPLANTATION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 34548413113     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.07.004     Document Type: Article

References (43)

1. Gu K., Cowie C.C., and Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA 281 (1999) 1291-1297
2. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 suppl 1 (2006) S4-S42
3. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
4. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
5. Fonseca V., Desouza C., Asnani S., and Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25 (2004) 153-175
6. Fonseca V.A. Risk factors for coronary heart disease in diabetes. Ann Intern Med 133 (2000) 154-156
7. Muntner P., He J., Chen J., Fonseca V., and Whelton P.K. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 14 (2004) 686-695
8. Despres J.P., Lamarche B., Mauriege P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 (1996) 952-957
9. Feener E.P., and King G.L. Vascular dysfunction in diabetes mellitus. Lancet 350 suppl 1 (1997) SI9-SI13
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
11. Dandona P., Aljada A., and Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45 (2002) 924-930
12. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
13. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., and Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27 (1996) 567-574
14. Quinones M.J., Hernandez-Pampaloni M., Schelbert H., et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 140 (2004) 700-708
15. Juonala M., Viikari J.S., Laitinen T., et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation 110 (2004) 2918-2923
16. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
17. Festa A., D'Agostino R.J., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
18. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., and Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282 (1999) 2131-2135
19. Festa A., D'Agostino Jr. R., Tracy R.P., and Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51 (2002) 1131-1137
20. McGill J.B., Schneider D.J., Arfken C.L., Lucore C.L., and Sobel B.E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43 (1994) 104-109
21. Tchernof A., Nolan A., Sites C.K., Ades P.A., and Poehlman E.T. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105 (2002) 564-569
22. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289 (2003) 1799-1804
23. Hamdy O., Ledbury S., Mullooly C., et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 26 (2003) 2119-2125
24. van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 345 (2001) 1359-1367
25. van den Berghe G., Wilmer A., Hermans G., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 354 (2006) 449-461
26. Chaudhuri A., Janicke D., Wilson M.F., et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 109 (2004) 849-854
27. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
28. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
29. Fonseca V.A., Reynolds T., Hemphill D., et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complicat 12 (1998) 181-186
30. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
31. Camp H.S., Li O., Wise S.C., et al. Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes 49 (2000) 539-547
32. Guo L., Zhang L., Sun Y., et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR γ agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 10 (2006) 349-360
33. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., and Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 3452-3456
34. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid-intima thickness in type 2 diabetes. JAMA 296 (2006) 2472-2581
35. Mazzone T. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention. Am J Med 120 suppl 9B (2007) S26-S32
36. Panunti B., and Fonseca V. Effects of PPAR γ agonists on cardiovascular function in obese, non-diabetic patients. Vascul Pharmacol 45 (2006) 29-35
37. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
38. Takagi T., Yamamuro A., Tamita K., et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146 (2003) e5
39. Choi D., Kim S.K., Choi S.H., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
40. Desouza C.V., Murthy S.N., Diez J., et al. Differential effects of peroxisome proliferator activator receptor-α and -γ ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J Cardiovasc Pharmacol Ther 8 (2003) 297-305
41. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
42. Sobel B.E. Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med 120 suppl 9B (2007) S3-S11
43. Inzucchi S.E., Masoudi F.A., Wang Y., et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28 (2005) 1680-1689